Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705793 | 0.92 | SMN1; SMN2 (0.39) | ALDH1A1THRBLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL27496194 | 0.88 | THRB (0.32) | ALDH1A1THRBLMNASMN1; SMN2 | |
| SCHEMBL440376 | 0.83 | THRB (0.40) | ALDH1A1THRBLMNA | |
| SCHEMBL7753817 | 0.83 | THRB (0.44) | THRBLMNAEPHX1SMPD1 | |
| SCHEMBL6227646 | 0.83 | THRB (0.44) | THRBLMNAEPHX1SMPD1 | |
| SCHEMBL12348921 | 0.83 | SMN1; SMN2 (0.32) | ALDH1A1LMNASMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL12349185 | 0.83 | SMN1; SMN2 (0.32) | ALDH1A1LMNASMN1; SMN2HSD17B10MEN1 | |
| Ammonia Solution, Strong SCHEMBL7956004 | 0.81 | THRB (0.38) | ALDH1A1THRBLMNA | |
| SCHEMBL16318547 | 0.81 | — | — | |
| SCHEMBL8431364 | 0.80 | THRB (0.42) | THRBLMNAEPHX1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146541-A1 | MACROCYCLIC COMPOUNDS AS USP1 INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-8076412-B2 | Water-soluble polymer alkanals | NEKTAR THERAPEUTICS (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | NEKTAR THERAPEUTICS (US) | 2011-02-10 | — | — | US | disclosed |
| CN-1842568-A | Polymer alloy, crosslinked object, and fuel hose | ZEON CORP (JP) | 2006-10-04 | — | — | CN | disclosed |
| CN-1688653-A | Polymer alloy, crosslinked material, and fuel pipe | ZEON CORP (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-0822217-B1 | HETEROTELECHELIC BLOCK COPOLYMERS AND PROCESS FOR PRODUCING THE SAME | KATAOKA KAZUNORI (JP) | 2002-10-23 | — | — | EP | disclosed |
| CN-1067073-C | Acyclic nucleoside derivatives | MEDIVIR AB (CH) | 2001-06-13 | — | — | CN | disclosed |
| US-5925720-A | CARRIER FOR DRUG DELIVERY | Kataoka, Kazunori (JP) | 1999-07-20 | — | — | US | disclosed |
| CN-1210537-A | Acyclic nucleoside derivatives | MEDIVIR AB (CH) | 1999-03-10 | — | — | CN | disclosed |
| EP-0822217-A1 | HETEROTELECHELIC BLOCK COPOLYMERS AND PROCESS FOR PRODUCING THE SAME | Kataoka, Kazunori (JP) | 1998-02-04 | — | — | EP | disclosed |
| US-4847229-A | Process for hydroformylation of unsaturated compounds using iron carbonyl catalysts | THE DOW CHEMICAL COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| US-4782188-A | Process for hydroformylation of unsaturated compounds using iron carbonyl catalysts | THE DOW CHEMICAL COMPANY (US) | 1988-11-01 | — | — | US | disclosed |
| US-4374999-A | RHODIUM-COBALT CLUSTER CATALYST LOADED ON AMINE RESIN | THE DOW CHEMICAL COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | ALK, ALKBH3, AQP1 | ALDH1A1 77/4885THRB 4877/4885LMNA 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.